BFRI vs BTAI

Biofrontera Inc. vs BioXcel Therapeutics, Inc. — Valuation Comparison 2026

BFRI

Drug Manufacturers - Specialty & Generic
Biofrontera Inc.
Quality
5.6
out of 10
Value Trap
30
LOW
Price
$0.86
Last close
Models
7/13
Active
VS

BTAI

Drug Manufacturers - Specialty & Generic
BioXcel Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$1.26
Last close
Models
4/13
Active

Model-by-Model Comparison

ModelType BFRI Fair ValueBFRI Upside BTAI Fair ValueBTAI Upside
Bayesian DCF Intrinsic $0.38 -55.8%
EROIC Spread Intrinsic $1.49 +24.3%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.72 +99.7%
PWERM Option-Based $1.91 +121.7% $3.72 +194.9%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BFRI vs BTAI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BFRI vs BTAI — Which Stock Is More Undervalued?

BFRI scores higher with a 5.6/10 quality rating vs BTAI's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Biofrontera Inc. (BFRI) and BioXcel Therapeutics, Inc. (BTAI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BFRI currently trades at $0.86 with a QOC of 5.6/10, while BTAI trades at $1.26 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).